.gif)
8/24/2010
PROLOR BIOTECH RECEIVES FDA CLEARANCE FOR A PHASE II TRIAL OF ITS LONG-ACTING HUMAN GROWTH HORMONE IN THE U.S.
8/2/2010
STUDY PUBLISHED IN THE JOURNAL ENDOCRINOLOGY FURTHER CONFIRMS THERAPEUTIC POTENTIAL OF PROLOR’S LONG-ACTING HUMAN GROWTH HORMONE
7/21/2010
PROLOR BIOTECH INITIATES PHASE II CLINICAL TRIAL OF ITS LONGER-ACTING VERSION OF HUMAN GROWTH HORMONE
6/29/2010
PROLOR BIOTECH GRANTED EU GMP CERTIFICATION FOR LEAD CANDIDATE HGH-CTP, A PRE-CONDITION FOR ITS PHASE II CLINICAL TRIAL
6/2/2010
PROLOR BIOTECH TO PRESENT AT THE JEFFERIES 2010 GLOBAL LIFE SCIENCES CONFERENCE
6/1/2010
PROLOR BIOTECH TO RING OPENING BELL AT THE NEW YORK STOCK EXCHANGE ON JUNE 3, 2010
5/26/2010
PROLOR BIOTECH ANNOUNCES NEW LISTING ON TEL AVIV STOCK EXCHANGE
5/11/2010
PROLOR BIOTECH TO PRESENT AT THE RODMAN & RENSHAW SIXTH ANNUAL GLOBAL HEALTHCARE CONFERENCE
5/3/2010
PROLOR BIOTECH REPORTS NEW PRECLINICAL DATA SUPPORTING THE ENHANCED BIOLOGICAL ACTIVITY POTENTIAL OF ITS BIOBETTER PIPELINE
4/30/2010
PROLOR BIOTECH SELECTED TO PRESENT AT THE 2010 BIO INTERNATIONAL CONVENTION
4/12/2010
PROLOR BIOTECH AWARDED ISRAELI GOVERNMENT GRANT OF UP TO $1.6 MILLION FOR ITS LONGER-ACTING HUMAN GROWTH HORMONE PROGRAM
3/25/2010
PROLOR BIOTECH AWARDED SECOND ISRAELI GOVERNMENT GRANT TO SUPPORT DEVELOPMENT OF ITS LONGER-ACTING INTERFERON BETA
3/25/2010
PROLOR BIOTECH ANNOUNCES NYSE AMEX LISTING
3/18/2010
PROLOR BIOTECH ANNOUNCES SALE OF $24.4 MILLION OF COMMON STOCK
3/5/2010
PROLOR BIOTECH TO PRESENT AT THE BIO-EUROPE SPRING 2010 CONFERENCE
2/2/2010
PROLOR BIOTECH REPORTS POSITIVE TOP-LINE RESULTS FROM PHASE I STUDY OF ITS LONGER-ACTING VERSION OF HUMAN GROWTH HORMONE
1/29/2010
PROLOR BIOTECH REPORTS MERCK RECEIVES FINAL MARKETING AUTHORIZATION IN EUROPE FOR LONG-ACTING CTP-MODIFIED FERTILITY TREATMENT ELONVA® (FSH-CTP)
1/25/2010
PROLOR BIOTECH REPORTS POSITIVE RESULTS FROM COMPARATIVE STUDY OF ITS LONGER-ACTING VERSION OF MULTIPLE SCLEROSIS DRUG INTERFERON BETA IN PRIMATES
1/18/2010
PROLOR BIOTECH TO PRESENT HUMAN GROWTH HORMONE CLINICAL PROGRAM UPDATE AT THE 12TH ANNUAL BIO CEO & INVESTOR CONFERENCE
11/24/2009
PROLOR BIOTECH REPORTS MERCK RECEIVES POSITIVE REGULATORY OPINION FOR EUROPEAN MARKETING OF LONG-ACTING CTP-MODIFIED FERTILITY TREATMENT ELONVA® (FSH-CTP)
9/16/2009
PROLOR BIOTECH ANNOUNCES INITIATION OF PHASE I CLINICAL TRIAL FOR ITS LONG-ACTING GROWTH HORMONE
9/16/2009
PROLOR BIOTECH TO PRESENT AT THE UBS 2009 GLOBAL LIFE SCIENCES CONFERENCE
7/27/2009
PROLOR BIOTECH ACQUIRES LICENSE OPTION FROM YEDA FOR DEVELOPMENT OF LONG-ACTING ANTI-OBESITY DRUG
7/24/2009
PROLOR BIOTECH ANNOUNCES $10 MILLION PREFERRED STOCK LINE FROM MEMBERS OF THE FROST GROUP
6/30/2009
PROLOR BIOTECH AWARDED TWO U.S. PATENTS FOR ITS LONGER-ACTING HUMAN GROWTH HORMONE AND LONGER-ACTING ERYTHROPOIETIN
6/12/2009
MODIGENE SHAREHOLDERS APPROVE COMPANY NAME CHANGE AND OTHER PROPOSALS AT ANNUAL MEETING
3/10/2009
MODIGENE TO PRESENT AT THE
BIO-EUROPE® SPRING 2009 CONFERENCE
2/10/2009
MODIGENE SETS RECORD DATE FOR
ANNUAL MEETING OF SHAREHOLDERS
1/27/2009
MODIGENE AWARDED SECOND-YEAR GRANT BY ISRAELI
GOVERNMENT TO SUPPORT DEVELOPMENT OF ITS
LONGER-ACTING HUMAN GROWTH HORMONE
1/15/2009
MODIGENE ANNOUNCES POSITIVE RESULTS OF PILOT TOXICITY
STUDY OF ITS LONG-ACTING HUMAN GROWTH HORMONE HGH-CTP
9/15/2008
MODIGENE TO PRESENT AT THE UBS
GLOBAL LIFE SCIENCES CONFERENCE
8/5/2008
MODIGENE AWARDED ISRAELI GOVERNMENT GRANT TO SUPPORT
DEVELOPMENT OF ITS LONGER ACTING INTERFERON BETA
7/10/2008
MODIGENE PLATFORM VALIDATED IN INDEPENDENT
PHASE III TRIAL OF CTP TECHNOLOGY
5/15/2008
MODIGENE TO PRESENT AT THE RODMAN & RENSHAW 5TH
ANNUAL GLOBAL HEALTHCARE CONFERENCE MAY 20 2008
3/27/2008
MODIGENE ANNOUNCES CLOSING OF $12 MILLION
FINANCING BY MEMBERS OF THE FROST GROUP
3/5/2008
MODIGENE ANNOUNCES APPOINTMENT OF
DR. PHILLIP FROST AS CHAIRMAN OF ITS BOARD OF
DIRECTORS
11/27/2007
MODIGENE AWARDED ISRAELI GOVERNMENT GRANT TO
SUPPORT DEVELOPMENT OF ITS LONGER-ACTING
HUMAN GROWTH HORMONE
10/31/2007
MODIGENE TO PRESENT AT ACUMEN BIOFIN RODMAN &
RENSHAW 9th ANNUAL HEALTHCARE CONFERENCE
.gif)
9/24/2007
Study Published in Endocrinology Reports Potential of
Modigene Technology to Extend Duration of Protein Drugs
9/18/2007
Modigene to Present at the UBS Global Life Sciences Conference
.gif)
8/29/2007
MODIGENE to Present at the Roth 2007 New York Investor Conference
.gif)
7/16/2007
Modigene Prepares to Advance Its Long-Acting Human Growth
Hormone Toward Clinical Trials Via GMP Manufacturing Agreement
.gif)
7/2/2007
Key Trials of Organon’s Long-Acting Fertility Drug Using
Modigene’s CTP Technology Achieve Clinical Trial Milestone
.gif)
6/20/2007
Modigene Announces Successful Completion of Pharmacokinetic
& Pharmacodynamic Pre-Clinical Experiments for Proprietary Long
- Acting Human Growth Hormone, Long-acting Interferon Beta and
Long-acting Erythropoietin
.gif)
5/22/2007
Modigene Announces Completion of Second and Final Closing
of Private Placement, Bringing Total Private Placement
Proceeds to $13 million.
.gif)
5/15/2007
Modigene Announces Closing of Merger and $9.6 Million
Private Placement, Appointment of Dr. Phillip Frost and Dr. Jane Hsiao
to its Board of Directors.
.gif)
2/15/2007
Modigene Announces Signing of Exclusive CTP Definitive
License Expansion Agreement With Washington University
in St. Louis.
.gif)
9/27/2006
Modigene Announces Approval Of Grant Awarded By The Israeli
Office Of The Chief Scientist To Its R&D Subsidiary,
ModigeneTech Ltd.
.gif)
3/1/2006
Modigene Announces Appointment of Bexxar®, Mylotarg®, and
CEA-Scan® Developer to its Scientific Advisory Board
.gif)
2/1/2006
Modigene Announces Three New Appointments to its Scientific
Advisory Board
.gif)
12/27/2005
Modigene Announces Signing of License Expansion Agreement with
Washington University of St. Louis
12/14/2005
Modigene Appoints Co-Developer of Five Therapeutic Proteins as Chief
Executive Officer
12/14/2005
Modigene Announces Closing of $3 Million funding
In order to view this file, you will need the Adobe® Acrobat® ReaderTM, a plug-in available from Adobe Systems, Inc. please click the below to obtain and install a copy of the plug-in.
